Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
How did your country report this? Share your view in the comments.
Diverging Reports Breakdown
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
Teva is engaging in the Offers to proactively manage and optimize its debt capital structure, and to extend the maturity profile of its debt. The Offers are being made pursuant and are subject to the terms and conditions set forth in the Offer to Purchase, dated May 19, 2025. Teva expects to fund the offers with the proceeds from the Financing Transaction (as defined below), together with cash on hand. The Notes are issued by finance subsidiaries of Teva and guaranteed by Teva. The aggregate purchase price (exclusive of accrued and unpaid interest) of the Notes is up to $2,000,000,.000 (equivalent) (the “ Total Maximum Amount ”) The Notes have a maturity date of February 9, 2027, and a coupon rate of 3.750% per year. They are being offered for cash in Euros per $1,000 or €1,00, with a maximum purchase price of $7,875,000 (including accrued interest)
Source: Finance.yahoo.com | Read full article
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
Teva is engaging in the Offers to proactively manage and optimize its debt capital structure, and to extend the maturity profile of its debt. The Offers are being made pursuant and are subject to the terms and conditions set forth in the Offer to Purchase, dated May 19, 2025 (the “Offer to Purchase”), available via the offer website: https://clients.dfkingltd.com/teva. Teva expects to fund the offers with the proceeds from the Financing Transaction (as defined below), together with cash on hand. The offer is being made by Teva Pharmaceutical Industries Ltd. (“Teva”) and its subsidiaries, Teva Finance Netherlands III B.V. and Teva pharmaceutical Finance Netherlands IV B.v. The tender offers are for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $2,000,000,.000 (equivalent) ( the “Total Maximum Amount’)
Source: Koreabizwire.com | Read full article
Teva Announces Launch of $2,000,000,000 (Equivalent)
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue $2,000,000,.000 (equivalent) of senior notes through its special purpose finance subsidiaries. Teva expects to use the net proceeds from the offerings, together with cash on hand, to fund the announced tender offers to purchase, for cash, its USD 3.150% Senior Notes due 2026, USD 4.750% Sustainability-Linked Senior notes due 2027, EUR 3.750%, USD 7.875% and EUR 7.375%. The tender offers are being made solely by the offer to purchase dated May 19, 2025. The offering of these Notes will be made only by means of a prospectus supplement and accompanying base prospectus, which have been filed with the Securities and Exchange Commission (the ‘SEC’) on February 7, 2025 and are available at no charge by visiting EDGAR on the SEC website at http://www.sec.gov.
Source: Globenewswire.com | Read full article
Teva Launches $2 Billion Debt Tender Offer to Optimize Capital Structure
Teva Announces $2,000,000,.000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031. Teva expects to fund the Offers with proceeds from the Financing Transaction (as defined below) The Offers are subject to the terms and conditions set forth in the Offer to Purchase, dated May 19, 2025 (the “Offer to Purchase offer”), available via the website: http://clkingd.com/teva/OfferToPurchases.html. The Notes are being offered for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $2.000,00,000 (equivalent) (“Total Maximum Amount”) Teva is engaging to proactively manage and optimize its debt structure, and to the the debt debt debt of the company. The notes are issued by finance subsidiaries of Teva and guaranteed by Teva: USD 3.150% Senior Notes due 2026, CUSIP 88167AAE1 / ISIN US88167 AAE10 (Registered), issued by TeVA Pharmaceutical Finance Netherlands III B.V. (the“ Pool 1 Notes �
Source: Stocktitan.net | Read full article
Global Perspectives Summary
Our analysis reveals how this story is being framed differently across global media outlets.
Cultural contexts, editorial biases, and regional relevance all contribute to these variations.
This diversity in coverage underscores the importance of consuming news from multiple sources.
Sources
- Original: Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
- Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
- Teva Announces Launch of $2,000,000,000 (Equivalent)
- Teva Launches $2 Billion Debt Tender Offer to Optimize Capital Structure
Source: https://finance.yahoo.com/news/teva-announces-2-000-000-085200945.html